New drug VT3989 targets Hard-to-Treat cancers in early trial
NCT ID NCT04665206
First seen Nov 01, 2025 · Last updated May 04, 2026 · Updated 25 times
Summary
This study tests an experimental drug called VT3989, taken daily by mouth, in people with advanced solid tumors, mesothelioma, or non-small cell lung cancer that has stopped responding to standard treatments. The main goals are to check the drug's safety and side effects, and to see if it can shrink tumors. The trial is open-label, meaning everyone knows they are getting the drug, and it involves both dose-finding and expansion phases.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SOLID TUMOR, ADULT are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Dana-Farber Cancer Institute
RECRUITINGBoston, Massachusetts, 02215, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Linear Clinical Research
RECRUITINGNedlands, Western Australia, 6009, Australia
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
M Health Fairview University of Minnesota Medical Center
RECRUITINGMinneapolis, Minnesota, 55455, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
MD Anderson Cancer Center
RECRUITINGHouston, Texas, 77030, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Massachusetts General Hospital
RECRUITINGBoston, Massachusetts, 02114, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Memorial Sloan Kettering Cancer Center
RECRUITINGNew York, New York, 10065, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Monash Health
RECRUITINGClayton, Victoria, 3168, Australia
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
NEXT Oncology
RECRUITINGSan Antonio, Texas, 78229, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Peter MacCullum Cancer Centre
RECRUITINGMelbourne, Victoria, 3000, Australia
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
UCSF Helen Diller Family Comprehensive Cancer Center
RECRUITINGSan Francisco, California, 94158, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
University of Chicago Medical Center
RECRUITINGChicago, Illinois, 60637, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Virginia Cancer Specialists, PC
RECRUITINGArlington, Virginia, 22201, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.